"I have a $17 stock for you that, if everything goes right, could easily trade up to $100 per share," Jim Cramer told viewers of his "Mad Money" TV show Friday. The stock is NMT Medical ( NMTI). It's not a buy-and-hold play, he said, but if you're willing to take some risk it could possibly make you some money fast off of people who suffer from severe migraines. There's a heart defect called patent foramen ovale (PFO) that affects one in five people and has been connected with an increased likelihood that a person will have migraines, Cramer said. If you close the hole in the heart caused by the defect, it could have a profound impact. NMT Medical has an implantable, stent-like device called CardioSEAL that could help plug this hole and is already being used to help with strokes, he said. And right now the company is trial testing the device to prove its effectiveness. If the trial works, I think you'll be hearing about it and paying $100 a share, Cramer said. But, he cautioned, the stock could go below $10 if the trial testing don't work out for the company. Still, Cramer thinks the potential upside outweighs the downside. He admitted that he can't say with any authority which way the study will go, but he can say what it will mean if the study shows that the product works. He came up with the $100-a-share number by looking at the figures NMT Medical offers, including the fact that 3 million people get migraines with aura, the kind associated with the PFO heart defect. These are people who miss work because their migraines are so bad, he added. Right now at $17 a share, the company has implanted less than 20,000 of these devices worldwide, Cramer said. But if the device proves effective, hundreds of thousands could want it, and there's not a lot of competition on the horizon, he said. He told a caller that drugmakers with migraine treatments will likely badmouth the product, but that the consumer will decide the winner in this battle and pick the product that actually takes away their pain. And while he typically does not recommend one-product players, he reminded viewers that buying this stock means going out on a limb and getting into a very speculative play.
Cramer ConcursNothing is more important than growth, Cramer reminded viewers, and that's why he likes Concur Technologies ( CNQR), which has seen amazing earnings growth and is likely to see more. The company's Web-based software automates the management of travel and entertainment expenses for businesses, Cramer said. And it can help stop employees from expensing things like strip club visits, a fraudulent perk popular on Wall Street, he added. Not only does stopping fraud help control costs, just having a machine do this work is 60% cheaper than hiring humans to do it, he said. But 90% of businesses still try to manage their T&E expenses themselves, so that means there's a lot of room for growth in the sector. Concur has 30% of the market right now, and Cramer said it should be able to gain more market share because it offers a superior product. He points out that the company has a 97% customer-retention rate. The stock is expensive, but it's a growth story, Cramer said, adding that he sees it going up a lot higher before it starts to come down.
One Exchange for AnotherReal estate is over as the asset of choice, so equities are back in for 2006, he told viewers. And the best way to play this trend is to buy Nasdaq Stock Market ( NDAQ) to get in on the major bull market in the exchanges. How does he know the exchanges are making money? Two weeks ago he recommended International Securities Exchange ( ISE) around $30, and now it's at $36. He said, if you listened to him then, he would now take profits out of International Securities Exchange and put it into Nasdaq Stock Market. Archipelago Holdings ( AX) is attractive, too, he said, but he likes Nasdaq better because it trades at a discount to Archipelago. Plus, he thinks that Nasdaq Stock Market is not getting the premium for having great management and the fact that it's buying Instinet will help boost its numbers, too.
Taking CallsA viewer said that Cramer had irresponsibly pushed CVS ( CVS) on
Lightning RoundCramer was bullish on Wendy's ( WEN), Sony ( SNE), Baker Hughes ( BHI), Microsoft ( MSFT), Automatic Data Processing ( ADP), Saks ( SKS), Goodyear Tire ( GT), Bentley Pharmaceuticals ( BNT), Rambus ( Rambus), Toyota ( TM), Rediff ( REDF), Cypress Semiconductor ( CY), Halliburton ( HAL)and Allegheny Technologies ( ATI). Cramer was bearish on: Computer Sciences ( CSC), Skyworks Solutions ( SWKS), Komag ( KOMG), Cooper Tire ( CTB), Wipro ( WIT), Pacific Sunwear ( PSUN), Abercrombie & Fitch ( ANF)and Charles & Colvard ( CTHR).
For more of Cramer's insights during the Lightning Round,